Imugene Ltd's Leslie Chong speaks to Proactive's Andrew Scott following the news of a $90 million placement to new and existing institutional and sophisticated investors as well as a share purchase plan for existing eligible shareholders to raise up to a further $5 million. She says the capital raised will be used to fund their clinical trial pipeline through to the end of 2025.
Imugene's Leslie Chong welcomes strong support for its $90 million placement
